This Week in Cell and Gene Therapy: 14 New Developments to Know (June 27, 2022)

This Week in Cell and Gene Therapy: 12 New Developments to Know (June 13, 2022)

This Week in Cell and Gene Therapy: 14 New Developments to Know (May 23, 2022)

This week in Cell and Gene Therapy: 14 New Developments to Know (May 9, 2022)

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. The U.S. FDA has lifted clinical holds on two Phase III clinical studies evaluating gene therapies being developed by Pfizer, based in New York, NY. On April 28th, Pfizer announced […]

12 Recent Developments in Cell and Gene Therapy as of April 22, 2022

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. In public offering news, Massachusetts-based Selecta Biosciences has announced a $38.7 million public offering to continue developing ImmTOR, its antigen-specific immune tolerance platform. Leading the private financing news, Cambridge-based cell […]

13 Recent Developments in Cell and Gene Therapy as of April 8, 2022

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Bristol Myers Squibb, based in New York, NY, has announced that the European Commission (EC) has granted Marketing Authorization for Breyanzi (lisocabtagene maraleucel; liso-cel), its CD19-targeted chimeric antigen receptor (CAR)-T […]

14 Recent Developments in Cell and Gene Therapy as of March 22, 2022

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. EdiGene, a gene-editing company based in Beijing, China, has entered a non-exclusive, worldwide license agreement with Boston Children’s Hospital (BCH) for intellectual property rights covering the upregulation of fetal hemoglobin […]

VIDEO: 5 Key Trends in Cell and Gene Therapy

Learn about these 5 key trends based on research featured in Cell Therapy and Gene Therapy Markets, 2021-2031 (published Feb. 2022), a recent report by Kalorama Information Cell and gene therapy products are transforming the treatment of many acquired diseases such as cancer, diabetes, Parkinson’s disease and genetic diseases to correct defective genetic material. Additionally, […]

11 Recent Developments in Cell and Gene Therapy as of March 2022

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. The US Patent and Trademark Office has ruled against a patent challenge by the University of California, Berkeley (UC Berkeley) over patents awarded to the Broad Institute of MIT and […]

Tenfold Growth for $5.2 Billion Cell and Gene Therapy Market from 2021-2031

“Oncology, cardiovascular-blood and genetic conditions will be key contributors to the cell and gene therapy market’s strong performance through 2031.” – Kalorama Information   It is an exciting and interesting time for companies involved in cell and gene therapy as the industry is forecast to grow tenfold between 2021 to 2031, according to leading medical […]